Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect

Richard Le Blanc(Hôpital Maisonneuve-Rosemont), Jean Roy(Hôpital Maisonneuve-Rosemont), Guy Sauvageau(Hôpital Maisonneuve-Rosemont), Jeannine Kassis(Hôpital Maisonneuve-Rosemont), Lambert Busque(Hôpital Maisonneuve-Rosemont), J Boileau(Hôpital Maisonneuve-Rosemont), Claude Perreault(Institute for Research in Immunology and Cancer), Jean‐Louis Hébert(Sorbonne Université), S Montminy-Métivier(Hôpital Maisonneuve-Rosemont), Daniel Belanger(Hôpital Maisonneuve-Rosemont), D-C Roy(Hôpital Maisonneuve-Rosemont), Douglas Fish(Hôpital Maisonneuve-Rosemont), F Letendre(Hôpital Maisonneuve-Rosemont), R Lavallée(Hôpital Maisonneuve-Rosemont), Robert Bélanger(Hôpital Maisonneuve-Rosemont)
Bone Marrow Transplantation
November 1, 2001
10.1038/sj.bmt.1703253
Cited by 70

Related Papers

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.4k
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Allergy|2014|1.2k
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
|Allergy|2004|1.1k
Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial
|The Lancet|2013|522
Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma
|Clinical & Experimental Allergy|2004|520